Drugs / Tacabrutideg
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07856004 | Oct 2026 → Jul 2027 expected | — | BeOne Medicines | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07005713 | Jul 2025 → Nov 2026 expected | chronic urticaria | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06634589 | Nov 2024 → Dec 2028 expected | B-cell non-Hodgkin lymphoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05006716 | Sep 2021 → Mar 2027 expected | Richter transformation, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +3 | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06973187 | Sep 2025 → Apr 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT06846671 | Apr 2025 → May 2028 expected | B-cell chronic lymphocytic leukemia | BeOne Medicines | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | BeOne Medicines | Results BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026 beonemedicines.com ↗
Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | BeOne Medicines | BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026 beonemedicines.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tacabrutideg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07856004 ↗ |
| Route | Oral | “Orally administered” NCT05006716 ↗ |
| Target | BTK | “Tacabrutideg is designed to attach to the BTK protein and tag it for removal” NCT05006716 ↗ |